{"id":20646,"date":"2023-03-22T18:36:00","date_gmt":"2023-03-22T10:36:00","guid":{"rendered":"https:\/\/flcube.com\/?p=20646"},"modified":"2025-01-06T18:38:55","modified_gmt":"2025-01-06T10:38:55","slug":"3sbio-inc-reports-7-5-revenue-growth-in-2022-financials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20646","title":{"rendered":"3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials"},"content":{"rendered":"\n

China-based 3SBio Inc. (HKG: 1530<\/a>) released its 2022 financial report, recording revenues of RMB 6.859 billion (USD 995.9 million), a 7.5% increase year-on-year (YOY). Net profits reached RMB 2.163 billion (USD 314 million), up 25.2% YOY. This marks a significant milestone in the company’s ongoing growth and expansion.<\/p>\n\n\n\n

Core Product Performance<\/strong>
The company’s core products, including TPIAO (recombinant human thrombopoietin [rhTPO]), Yisaipu (a biosimilar version of etanercept), and two forms of recombinant human erythropoietin (rhEPO), EPIAO and SEPO, maintained their leading positions in China. TPIAO, the world\u2019s only commercialized rhTPO product, renewed its National Reimbursement Drug List (NRDL) status in 2022 and generated RMB 3.397 billion (USD 493.2 million) in sales, up 10.3% YOY. EPIAO and SEPO combined for RMB 1.129 billion (USD 163.9 million) in sales, with a dominant 44.5% market share. Yisaipu, used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis, brought in RMB 512 million (USD 74.3 million), accounting for 27.1% of the domestic TNF\u03b1 inhibitor market.<\/p>\n\n\n\n

Additional Product Highlights<\/strong>
Cipterbin (inetetamab), an anti-HER2 monoclonal antibody approved for marketing in 2020, increased its market share and realized RMB 159 million (USD 23.08 million) in sales, up 138.1% YOY. The hair health product minoxidil also performed well, with RMB 891 million (USD 129.3 million) in sales, up 48.1% YOY. Additionally, the company’s CDMO business completed RMB 166 million (USD 24.1 million) in customer orders, up 49.6% YOY.<\/p>\n\n\n\n

Strategic Partnerships and Future Plans<\/strong>
During the period, 3SBio licensed its PD-1 inhibitor 609A to US firm Syncromune for global development and commercialization of its tumor immunotherapy Syncrovax. It also granted development and commercialization rights to Kelingyuan Pharma for Cipterbin as an antibody-drug conjugate (ADC) component and obtained Greater China rights to Cosmo Pharmaceuticals N.V.\u2019s Winlevi. The company expects to market eight products in 2023 and make market filings for a dozen products in the next three years.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[116,43,16,27,83,1061,107,18],"class_list":["post-20646","post","type-post","status-publish","format-standard","hentry","category-company","tag-3sbio","tag-biosimilars","tag-cancer","tag-finanical-reports","tag-her2","tag-hkg-1530","tag-immunotherapy","tag-pd-1-l1"],"yoast_head":"\n3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859 billion (USD 995.9 million), a 7.5% increase year-on-year (YOY). Net profits reached RMB 2.163 billion (USD 314 million), up 25.2% YOY. This marks a significant milestone in the company's ongoing growth and expansion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20646\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20646\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-22T10:36:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-06T10:38:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20646#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20646\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials\",\"datePublished\":\"2023-03-22T10:36:00+00:00\",\"dateModified\":\"2025-01-06T10:38:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20646\"},\"wordCount\":295,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"3SBio\",\"Biosimilars\",\"Cancer\",\"Finanical Reports\",\"HER2\",\"HKG: 1530\",\"Immunotherapy\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20646#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20646\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20646\",\"name\":\"3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-22T10:36:00+00:00\",\"dateModified\":\"2025-01-06T10:38:55+00:00\",\"description\":\"China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859 billion (USD 995.9 million), a 7.5% increase year-on-year (YOY). Net profits reached RMB 2.163 billion (USD 314 million), up 25.2% YOY. This marks a significant milestone in the company's ongoing growth and expansion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20646#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20646\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20646#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials - Insight, China's Pharmaceutical Industry","description":"China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859 billion (USD 995.9 million), a 7.5% increase year-on-year (YOY). Net profits reached RMB 2.163 billion (USD 314 million), up 25.2% YOY. This marks a significant milestone in the company's ongoing growth and expansion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20646","og_locale":"en_US","og_type":"article","og_title":"3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20646","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-22T10:36:00+00:00","article_modified_time":"2025-01-06T10:38:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20646#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20646"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials","datePublished":"2023-03-22T10:36:00+00:00","dateModified":"2025-01-06T10:38:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20646"},"wordCount":295,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["3SBio","Biosimilars","Cancer","Finanical Reports","HER2","HKG: 1530","Immunotherapy","PD-1\/L1"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20646#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20646","url":"https:\/\/flcube.com\/?p=20646","name":"3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-22T10:36:00+00:00","dateModified":"2025-01-06T10:38:55+00:00","description":"China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859 billion (USD 995.9 million), a 7.5% increase year-on-year (YOY). Net profits reached RMB 2.163 billion (USD 314 million), up 25.2% YOY. This marks a significant milestone in the company's ongoing growth and expansion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20646#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20646"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20646#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20646"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20646\/revisions"}],"predecessor-version":[{"id":20647,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20646\/revisions\/20647"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}